Local drugmakers to challenge Baraclude in generics fight

Korean pharmaceutical firms are gearing up to enter the 100 billion won anti-hepatitis B drug market as the patent of the market leader, Bristol-Myers Squibb (BMS)’s Baraclude (entecavir), is to expire in 2015.

The Korea Food and Drug Administration said last Friday that it has approved the generic version of Baraclude, adding that a total of 41 bioequivalence tests await its approval.

Th...